Biogen Presents Phase 2 CELIA Data for Diranersen (BIIB080) at AAIC 2026 Tuesday July 14 Developing Topics in Phase 2 Clinical Trials Session: 18-Month Study in Early Alzheimer's Disease Is the First Tau-Targeting Antisense Oligonucleotide (ASO) to Show Both Reduction in Tau Pathology and Cognitive Benefit, Building on May 2026 Topline Announcement; Program Now Advances Toward Phase 3 Development With Clinical, Biomarker, and Safety Data Characterizing the Investigational Molecule
Biogen (NASDAQ: BIIB) will present Phase 2 CELIA study data for diranersen (BIIB080), an investigational tau-targeting antisense oligonucleotide (ASO), at AAIC 2026 in London during the Developing Topics in Phase 2 Clinical Trials session on Tuesday July 14, 2:00–3:30 PM BST. The 18-month CELIA study evaluated diranersen in patients with early Alzheimer's disease and is the first study to show reduction in tau pathology and cognitive benefit for a tau-targeted therapy. Biogen will present clinical, biomarker, and safety data that build on the May 2026 topline announcement and further characterize the molecule as the program advances toward Phase 3 development. Diranersen targets MAPT RNA to reduce tau production at its source, a differentiated approach to addressing abnormal tau both inside and outside neurons. The CELIA readout is a peptide-adjacent nucleic-acid biologic milestone that shifts the tau treatment conversation from 'reducing pathology' to 'reducing pathology and moving cognition.'